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Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone
receptor superfamily. Their discovery in the 1990s provided insights into the cellular mechanisms involved in the control of energy
homeostasis, the regulation of cell diﬀerentiation, proliferation, and apoptosis, and the modulation of important biological and
pathological processes related to inﬂammation and cancer biology, among others. Since then, PPARs have become an exciting
targetforthedevelopmentoftherapiesdirectedatmanydisordersincludingcancer.PPARsareexpressedinmanytumorsincluding
lung cancer, and their function has been linked to the process of carcinogenesis. Consequently, intense research is being conducted
in this area with the hope of discovering new PPAR-related therapeutic targets for the treatment of lung cancer. This review
summarizes the research being conducted in this area, and focuses on the mechanisms by which a member of this family (PPARγ)
is believed to aﬀect lung tumor cell biology.
Copyright © 2008 S. W. Han and J. Roman. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Lung carcinoma is one of the most common malignant
tumors in the world, and is the leading cause of carcinoma
death in USA [1]. Primary malignant cancers of the lung are
classiﬁed into small cell lung cancer (SCLC) and nonsmall
cell lung cancer (NSCLC). NSCLC accounts for 80% of
malignant lung cancer, and SCLC constitutes the remainder
[2]. Based on the cellular phenotype, NSCLC is further
subdivided into squamous cell carcinoma, adenocarcinoma,
and large cell carcinomas [3]. Despite advances in under-
standing the mechanisms involved in carcinogenesis, the
development of new surgical procedures, and the use of new
radio and chemotherapeutic protocols, the ﬁve-year survival
rate for lung cancer patients is poor and remains less than
15% [1]. This underscores the desperate need for novel
strategies for early detection, prevention, and treatment of
this malignancy.
Since their discovery in 1990, peroxisome proliferator-
activated receptors (also known as PPARs) have captured
the attention of investigators interested in learning about
the intracellular pathways that control signal transduction
and gene transcription. PPARs were originally cloned in an
attempt to identify the molecular mediators of peroxisome
proliferation in the liver of rodents. Today, PPARs are rec-
ognized as versatile members of the ligand-activated nuclear
hormone receptor superfamily of transcription factors that
includes receptors for steroids, thyroid hormone, retinoic
acid,andvitaminD,amongothers[4].PPARsareconsidered
to play key roles in diverse physiological processes ranging
from lipid metabolism to inﬂammation, and have been
implicated in diseases such as cancer, atherosclerosis, and
diabetes [4, 5]. Although information about the function of
PPARs in lung is scarce, data implicating these molecules in
key processes in lung biology are rapidly emerging.
Three subtypes of PPARs have been identiﬁed and
cloned: PPARα,P P A R β/δ,a n dP P A R γ. These subtypes are
distinguished by their tissue distribution, and to a lesser
degree,bytheirligandspeciﬁcity.PPARαhasbeenimplicated
inhepatocellularcarcinomainrodents,whereasactivationof
PAPRβ/δ promotes human lung carcinoma cell proliferation
through PI3-Kinase/Akt activation [6]. However, of the2 PPAR Research
three PPARs identiﬁed to date, PPARγ represents the most
promising target in view of the many reports implicating
this molecule in lung carcinoma cell growth both in vitro
and in vivo. This review focuses on PPARγ, its role in lung
carcinogenesis, and the potential therapeutic role of PPARγ
agonists in lung cancer.
2. ELUCIDATING THE FUNCTION OF PPARγ
PPARγ was discovered based on its similarity to PPARα,
and it is the most intensively studied ligand-dependent
transcriptionalregulator.Byutilizingthreediﬀerentpromot-
ers, a single PPARγ gene encodes three isoforms, namely,
PPARγ1, PPARγ2, and PPARγ3[ 7]. Analysis of PPARγ1
and γ3 transcripts revealed that they both translate into
the same PPARγ1p r o t e i n[ 8]. PPARγ2 protein contains
additional 30 amino acids at its N-terminus compared to
PPARγ1. PPARγ is highly expressed in adipose tissue, and
it is a master regulator of adipocyte diﬀerentiation [9, 10].
In addition to its role in adipogenesis, PPARγ serves as
an important transcriptional regulator of glucose and lipid
metabolism, and it has been implicated in the regulation
of insulin sensitivity, atherosclerosis, and inﬂammation [11,
12]. PPARγ is also expressed in multiple other tissues
such as breast, colon, lung, ovary, prostate, and thyroid,
where it was demonstrated to regulate cellular proliferation,
diﬀerentiation, and apoptosis [13, 14]. As will be discussed
later,PPARγ activationinhibitstumorprogressioninNSCLC
[15, 16]. Several leukocyte populations, including mono-
cytes/macrophages, lymphocytes, and dendritic cells, have
also been shown to express PPARγ suggesting a role for this
moleculeintheregulationofimmuneresponses[17].PPARγ
has been described as a negative regulator of macrophage
function since its activation suppresses the production
of inﬂammatory cytokines, chemokines, metalloproteases,
and nitric oxide [18, 19]. These PPARγ-mediated anti-
inﬂammatory eﬀects are not restricted to monocytes, as
the treatment with PPARγ agonists results in inhibition
of cytokine/chemokine production in several epithelial and
stromal cells [15].
Several natural and synthetic compounds have been
identiﬁed as activators of PPARγ. The insulin-sensitizing
antidiabetic drugs known as thiazolidinediones (TZDs) were
the ﬁrst compounds identiﬁed as PPARγ agonists [20]. The
TZDs’ rosiglitazone and pioglitazone are currently in clinical
use for the treatment of type II diabetes, while troglitazone
was withdrawn from clinical use because it was linked to
idiosyncratic liver toxicity [21]. Other non-TZD synthetic
ligands include certain nonsteroidal anti-inﬂammatory
drugs such as isoxazolidinone JTT-501 [22] and tyrosine-
based GW7845 [23]. Naturally occurring compounds that
activate PPARγ include long-chain polyunsaturated fatty
acids which are found in ﬁsh oil (e.g., n-3-PUFA and n-6-
PUFA), eicosanoids (e.g., 15d-PGJ2), lipid hydroperoxides
(e.g., 9(s)-HODE and 13(s)-HODE), as well as linoleic
acid, 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2), 12/15
lipoxygenase products of 15-hydroxyeicosatetraenoic acid
(15-HETE), and 13-hydroxyoctadecadienoic acid [24–26].
In addition, compounds from several medicinal plants such
as Saurufuran A from Saururus chinensis [27], ﬂavonoids
like chrysin and kaempferol [28], phenolic compounds from
Glycyrrhiza uralensis [29], and curcumin from Curcumin
longa [30, 31] are also shown to activate PPARγ.
Thesyntheticligandsandsomenaturalligandshavebeen
used to elucidate the role of PPARγ in cellular functions
both in vitro and in vivo. However, several caveats should
be taken into consideration when interpreting such studies.
First, the natural ligands that regulate PPARs in vivohave
not been completely elucidated. Second, not all PPARγ
ligandsexerttheireﬀectsthroughPPARγ sincethereisstrong
evidence for the activation of PPARγ-independent signals,
particularly with the natural ligand 15d-PGJ2.T h i r d ,h i g h -
aﬃnity ligands for PPARγ (e.g., TZDs) may exert partial
agonist/antagonist activity [32]. The latter might be due
to the fact that individual TZDs induce diﬀerent PPARγ
conformations that inﬂuence the recruitment of diﬀerent
coactivator/corepressor molecules. Thus, the activity of the
PPARγ transcriptional complex is inﬂuenced by the context
of a given gene and its promoter, and by the relative
availability of pertinent coactivator/corepressor molecules in
the cell or tissue of interest.
3. PPARγ IN LUNG CANCER
Among the three subtypes, the role of PPARγ has been
investigated the most in lung carcinogenesis. PPARγ is
expressed in many cancers including colon, breast, and
prostate cancers, and with few exceptions, PPARγ ligands
are antiproliferative in these cancers. Similarly, PPARγ is
expressed in SCLC and NSCLC [33]. Furthermore, PPARγ
ligandsinducegrowtharrestandpromotechangesassociated
with diﬀerentiation as well as apoptosis in a variety of
lung carcinoma cell lines although most of the knowledge
available in this area has been generated in NSCLC [34, 35].
The exact mechanisms linking modulation of PPARγ with
cancer growth inhibition remain unclear. However, current
evidence suggests that PPARγ ligands aﬀect a number
of mechanisms including regulation of the intracellular
machinery involved in cell signaling and cell cycle control,
inhibition of mitogenic factors and tumor promoters, pre-
vention of tumor cell recognition of extracellular mitogenic
signals, breakdown of nicotine-induced cell survival, and
modulation of the expression of angiogenic factors needed
for the development of the vascular networks that supply
tumor cell (see Figure 1). These mechanisms are discussed
below as they relate to the action of PPARγ ligands in lung
cancer.
SeveralstudiesdemonstratethatPPARγ ligandsaﬀectcell
cycle control in tumor cells. For example, PPARγ ligands
have been found to inhibit the growth of A549 adenocar-
cinoma cells due to G0/G1 cell cycle arrest through the
upregulation of mitogen-activated protein kinases ERK1/2
and the downregulation of G1 cyclins D and E [15]. Trogli-
tazone inhibits NSCLC proliferation in part by stimulating
the expression of the GADD 153 (for growth arrest and
DNA damage-inducible gene-153) [36]. Also, troglitazone
was found to induce apoptosis in NCI-H23 cells via a
mitochondrial pathway through the activation of ERK1/2S. W. Han and J. Roman 3
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Figure 1:AnticanceractionsofPPARγ ligands. Inadditiontogenetic abnormalities,lungcarcinoma cells receive mitogenic andantiapoptotic
signals that promote their progression and metastasis through the activation of key intracellular pathways (e.g., COX-2, Akt, and mTOR).
Lung carcinoma cells recognize these signals via diverse receptors for growth factors (e.g., EGFR), prostanoids (e.g., EP2 and EP4),
and extracellular matrices (e.g., integrins), among others. In addition, angiogenic factors assist in the vascularization of tumors, while
inﬂammatory signals further promote tumor progression. PPARγ ligands inhibit tumor growth in animal models, but the mechanisms
responsible for these eﬀects appear to be multidimensional. In vitro studies reveal that PPARγ ligands aﬀect tumors by inhibiting the
expression of key prostanoid and integrin receptors, by reducing the expression of ﬁbronectin, a matrix glycoprotein that stimulates
tumor cell proliferation, and by inhibiting the production of angiogenic and inﬂammatory signals. In addition, PPARγ ligands increase
the expression and/or activity of tumor suppressors like PTEN and p21. Although many of these anticancer eﬀects are mediated through
PPARγ, others appear to be independent of this nuclear transcription factor (e.g., via targeting TSC2, AMPK, and ROS production and ERK
activation, and interacting with CRE, AP-1).
[37]. Others have shown similar results using CRL-202 cells,
and further demonstrated that troglitazone downregulated
the expression of the antiapoptotic molecules Bcl-w and Bcl-
2,aswellasdecreasingtheactivityofSAPK/JNK[38].PPARγ
ligands also induce the expression of death receptor 5 (DR5)
and increase DR5 distribution at the cell surface in addition
to reducing c-FLIP levels in human lung cancer cells. These
agents cooperated with TRAIL to enhance apoptosis in
human lung carcinoma cells [39]. One recent report found
that PPARγ ligands 1-[(trans-methylimino-N-oxy)-6-(2-
morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid
ethyl ester (KR-62980)] and rosiglitazone induce NSCLC
apoptotic cell death mainly through PPARγ-dependent
reactive oxygen species formation via increased expression of
proline oxidase, a redox enzyme expressed in mitochondria
[35].
Tumor suppressor genes are also aﬀected by PPARγ
ligands. For example, PGJ2 and ciglitazone stimulated the
expression of p21 mRNA and protein expression in NSCLC,
and this coincided with a reduction in cyclin D1 mRNA
expression [40]. Of note, p21 antisense oligonucleotides
signiﬁcantly blocked lung carcinoma cell growth inhibi-
tion observed with PPARγ ligands, thereby establishing an
important role for p21 in this process. These ﬁndings are
consistentwiththoseofothersshowingthattheproliferation
of A549 cells injected subcutaneously into nude mice was
inhibited signiﬁcantly by treatment with ciglitazone, and
this coincided with increased expression of PPARγ and p21
and with downregulation of cyclin D1 [41]. A connection
between another tumor suppressor gene (p53) and PPARγ
ligands has also been demonstrated by showing that 15-
deoxy-PGJ2, together with docetaxel, stimulates apoptosis
in NSCLC through inhibition of Bcl2 and cyclin D1 and
overexpression of caspases and p53 [34].
Other reports implicate alterations in the mammalian
target of rapamycin (mTOR) signaling pathway in the
antitumor eﬀects of PPARγ ligands. Rosiglitazone, for
example, was reported to reduce the phosphorylation of
Akt, an upstream positive modulator of mTOR, and to
increase PTEN, a negative modulator of mTOR, in NSCLC
H1792 and H1838 cells; this resulted in inhibition of cell
proliferation [42]. Although the eﬀects of rosiglitazone on
Akt and PTEN were blocked by the selective PPARγ antag-
onist GW9662 and restored by transient overexpression of
PPARγ, cell growth was not entirely restored suggesting the
involvement of additional PPARγ-independent mechanisms
of action. Further work revealed that rosiglitazone increased
the phosphorylation of AMPKα,at a r g e to fL K B 1 ,a n dT S C 2 ,
another potential tumor suppressor and upstream down-
regulator of mTOR. The latter pathway was independent4 PPAR Research
of PPARγ since GW9662 and PPARγ siRNA did not aﬀect
it [42, 43]; others have shown similar increases in PTEN
expression induced by rosiglitazone [44].
More recently, we found that rosiglitazone and dietary
compounds such as ﬁsh oil (which contain certain kinds
of fatty acids like ω3a n dω6 polyunsaturated fatty acids
known to work as PPARγ ligands) inhibit integrin-linked
kinase (ILK) expression through PPARγ signaling and the
recruitment of a PPARγ coactivator, PGC-1α (Han et al.,
unpublished data). ILK is a unique intracellular adaptor
and kinase that links cell-adhesion receptors, integrins, and
growth factors to the actin cytoskeleton and to a range
of signaling pathways that are implicated in the regula-
tion of anchorage-dependent tumor cell growth/survival,
cell cycle progression, invasion and migration, and tumor
angiogenesis [45]. This eﬀect was associated with activation
of p38 MAPK followed by induction of transcription factor
AP-2α. In turn, this resulted in inhibition of NSCLC cell
proliferation (Han et al., unpublished data).
Several studies suggest that PPARγ ligands also exert
antitumor eﬀects by blocking access to mitogenic agents
such as PGE2, a major cyclooxygenase metabolite that
plays important roles in tumor biology. The functions of
PGE2 are mediated through one or more of its receptors:
EP1, EP2, EP3, and EP4 [46]. Human NSCLC cell lines
express EP2 receptors, among other EP receptors, and the
inhibition of cell growth by PPARγ ligands like GW1929,
PGJ2, ciglitazone, troglitazone, and rosiglitazone is associ-
ated with a signiﬁcant decrease in EP2 mRNA and protein
expression. Notably, the inhibitory eﬀects of rosiglitazone
and ciglitazone, but not PGJ2, were reversed by a speciﬁc
PPARγ antagonist GW9662, suggesting the involvement
of PPARγ-dependent and PPARγ-independent mechanisms
[46]. Also, a recent study showed that ciglitazone suppressed
cyclooxygenase-2 (COX-2) mRNA expression and COX-2
promoter activity, while upregulating peroxisome prolifera-
tors’ response element (PPRE) promoter activity in NSCLC
cells, further suggesting a negative modulator role for PPARγ
ligands in the COX-2/PGE2 pathway in NSCLC [47].
Nicotine, a major component of tobacco, stimulates
NSCLC cell proliferation through nicotinic acetylcholine
receptor- (nAChR-) mediated signals. A recent case-control
study of 500 incident lung cancer cases and 517 age
and sex frequency-matched cancer-free controls suggested
that PPARγ polymorphisms in Chinese smokers may con-
tribute to the etiology of lung cancer [48]. Monocytes
and monocyte-derived macrophages from healthy smokers
showed increased PPARγ expression as compared to those
from healthy nonsmokers, which were reproduced by nico-
tine in vitro [49]. Interestingly, concomitant administration
of PPARγ agonists can eﬀectively attenuate the eﬀects of
nicotine on alveolar type II cells [50]. We recently found
that rosiglitazone reduced nicotine-induced NSCLC cell
growth through downregulation of α7 nAChR-dependent
signals including ERK and p38 MAPK; this eﬀect appeared
to be PPARγ-independent (Han et al., unpublished data).
If conﬁrmed, this may unveil a novel mechanism by
which rosiglitazone inhibits human lung carcinoma cell
growth.
Other studies suggest that PPARγ ligands might pre-
vent the interaction of tumor cells with their surrounding
stromata, thereby interfering with host-derived and tumor-
derived factors and mitogenic and prosurvival eﬀects. An
example of this is ﬁbronectin, a matrix glycoprotein residing
in the lung stroma that is increased in most, if not all,
chronic forms of lung disease [51]. This is true for tobacco-
related lung disorders and ﬁbrotic disorders—all associated
with increased incidence of lung cancer [52]. Several studies
suggest that ﬁbronectin serves as a mitogen and survival
factor for NSCLC [53], and ﬁbronectin has been recently
shown to stimulate tumor cell expression of matrix metallo-
proteinases, proteases implicated in metastatic disease [54].
These observations support the idea that tumor cell interac-
tions with ﬁbronectin through surface integrin receptors are
advantageous for tumors since they stimulate proliferation,
survival, and metastases [53]. This idea remains to be
proven in vivo, but if found to be true, this might unveil a
new target for anticancer strategies. In this regard, PPARγ
ligands were shown to inhibit ﬁbronectin expression in
NSCLC cells by inhibiting transcription factors involved
in regulation of ﬁbronectin gene expression [55]. PPARγ
ligands (rosiglitazone and GW1929, but not PGJ2)h a v e
been also recently reported to inhibit the expression of
the gene encoding for the α5 integrin subunit resulting
in reduced expression of the integrin α5β1, a ﬁbronectin
receptor that mediates ﬁbronectin’s mitogenic eﬀects in
NSCLC cells and nontumor lung cells [56]. Thus, by
inhibiting the expression of ﬁbronectin and its integrin
α5β1, PPARγ ligands might reduce tumor cell recognition of
ﬁbronectin with consequent changes in cell proliferation and
apoptosis.
PPARγ might also regulate the generation of the complex
vascular network that supplies tumor cells. This idea is
supported by studies showing a reduction in blood vessel
density in the lung tumors generated by the injection
of A549 cells into the ﬂanks of SCID mice treated with
PPARγ ligands [57]. In in vitro studies, the treatment of
A549 cells with troglitazone or their transient transfection
with a constitutively active PPARγ construct blocked the
production of angiogenic molecules such as ELR+CXC
chemokinesIL-8(CXC-8),ENA-78(CXCL5),andGro-alpha
(CXCL1)[57].Furthermore,PPARγ activationinhibitedNF-
κB, a transcription factor known to regulate the expression
of many of the proangiogenic factors mentioned above.
Similarly, rosiglitazone was shown to inhibit mouse lung
tumor cell growth and metastasis in vivo through direct
and indirect antiangiogenic eﬀects [16]. It is important to
note that PPARγ signaling has also been associated with
tumor promoter activities in some tumor cells such as colon
and breast, and that this eﬀect was linked to increased
beta-catenin and c-Myc expression [58, 59]( Table 1). These
ﬁndings need to be conﬁrmed and tested in other tumors.
However, these data suggest that activation of speciﬁc
PPARγ-relatedpathwaysmaydiﬀerdependinguponthecells
and tumors examined. More than one pathway was involved
in the eﬀect of PPARγ ligands in one cell line which was
not observed in others. Internal genetic variations and other
factors may be responsible for these outcomes, and theseS. W. Han and J. Roman 5
Table 1: PPARγ-dependent signals in mediating the eﬀects of PPARγ ligands.
(1) PPARγ ligands inhibit cancer cell growth and induce apoptosis via:
↓ PGE2 receptors (e.g., EP2 and EP4)
↑ Tumor suppressors (e.g., PTEN, p21)
↓ Inﬂammatory factors (e.g., NF-κB, MCP-1, COX-2)
↓ Angiogenic factors (e.g., VEGF)
↓ Survival factors (e.g., PI3-K/Akt, mTOR)
↑↓ Other kinase signals (e.g., ERK, p38 MAPK)
↓ Growth factor receptors (e.g., EGF-R, PDGF-R)
↓ Extracellular matrices (e.g., ﬁbronectin, MMP-9)
↓ Integrin receptors (e.g., α5β1)
↑↓ Others (e.g., cytokines (e.g., IL-13, IL-21, TGF-β1) and chemokines (e.g., MIP-1β))
need to be explored further followed by conﬁrmation in in
vivo models of cancer.
4. IMPLICATIONS FOR THERAPY
The studies mentioned above suggest that PPARs are
involved in lung cancer cell biology. However, their roles
remain uncertain and much needs to be learned before they
are targeted for therapeutic intervention, especially when
considering PPARγ. Nevertheless, activation of PPARγ is
strongly associated with decreased lung carcinoma cell pro-
liferation both in vitro and in vivo. Furthermore, in primary
NSCLC, the expression of PPARγ has been correlated with
tumor histological type and grade, and decreased PPARγ
expression was correlated with poor prognosis [60]. Because
of this and the fact that synthetic agonists of PPARγ with
good safety proﬁles are currently in use in the clinical
arena, PPARγ has emerged as a reasonable target for the
development of novel antilung cancer therapies. Synthetic
and natural PPARγ activators might be useful as well. For
example, arachidonic acid inhibits the growth of A549 cells,
and this eﬀect is blocked by the synthetic PPARγ inhibitor
GW9662 [61]. MK886, a 5-lipoxygenase activating protein-
directed inhibitor, stimulates apoptosis and reduces the
growth of A549 cells through activation of PPARγ [62].
These and related drugs can be used alone or in combination
with other drugs for synergistic eﬀects. This was observed
when using low doses of MK886 in combination with
ciglitazone and 13-cis-retinoic acid on A549 and H1299 cells
[62]. Also, dramatic synergistic anticancer eﬀects have been
reported for lovastatin (an HMG-CoA reductase inhibitor)
andthePPARγ ligandtroglitazoneinseveralcelllinesinclud-
ing lung cancer cells [63]. An enhancement of the antitumor
eﬀects of geﬁtinib by rosiglitazone on A549 cell growth has
been recently noted, suggesting that combination strategies
using selective nuclear receptor activators in conjunction
with epidermal growth factor receptor inhibitors might be
eﬀective [64].
A recent study demonstrated that combining the PPARγ
ligand rosiglitazone with carboplatin dramatically reduced
lung tumor growth in vivo [65]. More tantalizing data
were derived from retrospective analysis demonstrating that
thiazolidinedione (TZD) use was associated with reduced
risk of lung cancer. This study revealed 33% reduction in
lung cancer risk among thiazolidinedione users as compared
to the nonusers after adjusting other variables [66]. Interest-
ingly, similar risk reduction was not observed for colorectal
and prostate cancers [66].
Despite the above, enthusiasm for the use of PPARγ
ligands as anticancer agents should be tempered by the fact
that PPARγ ligands stimulated PPARγ transactivation in
lung adenocarcinoma cell lines, while few to no eﬀects were
noted in squamous cell or large cell carcinomas. Also, it is
important that we better deﬁne PPARγ-independent path-
way to avoid unforeseen events and to identify new targets
for intervention [64, 67]( Table 2). Furthermore, a novel
splice variant of human PPARγ1 which is expressed strongly
in tumor tissues of primary human lung SCC has been
recently identiﬁed. This splice variant exhibits dominant-
negative properties in human lung tumor cells, and its
overexpression renders transfected cells more resistant to
chemotherapeutic drug- and chemical-induced cell death
[68]. This suggests that the decreased drug sensitivity of
PPARγ1-expressing cells may be associated with increased
tumor aggressiveness and poor clinical prognosis in patients.
Thus, a better understanding of the mechanisms of action of
activated PPARs in tumors (and host cells) is required since
the dissection of these pathways might unveil better targets
for therapy. Nevertheless, the data available to date regarding
PPARγ are promising and justify engaging in clinical studies
to determine the true role of PPARγ ligands in lung cancer,
while further work should be performed to identify more
selective and eﬀective strategies.
5. CONCLUSION
In summary, although its exact role in controlling lung
tumor growth and apoptosis remains undeﬁned, PPARγ has
been implicated both as a tumor suppressor (in most cases)
and as a tumor promoter (in rare cases). Hence, targeting
this receptor for therapeutic purposes while minimizing side
eﬀects represents a great challenge. Nevertheless, it is clear
that selective PPARγ modulation of desired gene sets can
be achieved by targeting corepressor interactions, separating
transactivation from transrepression, and favoring speciﬁc
subsets of coactivators. Although the exact mechanisms6 PPAR Research
Table 2: PPARγ-independent signals triggered by PPARγ ligands.
(2) PPARγ ligands stimulate cancer cell growth and reduce apoptosis via:
↑ Wnt signaling and oncogenes (e.g., cyclin D1, β-catenin, c-myc)
↑ Tumor suppressors (e.g., LKB1, AMPK, TSC2)
↑ ROS production and ERK activation (note that this also occurs in PPARγ-dependent pathways)
↓ Eﬀects on transcription factors (e.g., AP-1, NF-κB, Smads, Sp1, CRE)
mediating this eﬀect remain incompletely elucidated, data
available to date regarding this member of the PPAR
family are promising and justify engaging in prospective,
randomized clinical studies to determine the true role of
PPARγ ligands in lung cancer biology.
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